AbbVie Shares Surge on Strong Earnings and Drug Sales Hit $1.21 Billion in Trading Volume Rank 69th

On August 20, 2025, AbbVie (ABBV) saw a 1.44% rise in share price, with a trading volume of $1.21 billion, ranking it 69th in the market. The stock’s performance was driven by its second-quarter results, which exceeded earnings and revenue expectations. Earnings per share reached $2.97, up 12.1% year-over-year, while revenues hit $15.42 billion, reflecting 6.6% growth. Strong sales of key drugs like Rinvoq, Skyrizi, and Venclexta, along with newer therapies such as Ubrelvy and Qulipta, offset declines in Humira and Imbruvica. AbbVie also raised its 2025 revenue and EPS guidance for the second time this year, projecting adjusted EPS between $11.88 and $12.08 and total revenues near $60.5 billion.

The company’s transition from Humira, which has seen over 50% sales declines due to biosimilar competition, has been mitigated by robust growth in its immunology segment. Skyrizi and Rinvoq combined generated $11.6 billion in the first half of 2025, with annualized sales nearing $26 billion. These drugs are gaining traction in inflammatory bowel disease and other indications, supported by favorable head-to-head data. Additionally, AbbVie’s oncology portfolio, including Venclexta and newer acquisitions like Elahere, contributed to a 4.2% year-over-year revenue increase in the segment.

Recent strategic moves, such as the acquisition of Capstan Therapeutics and a licensing deal with Gubra for an obesity treatment, signal AbbVie’s focus on expanding its pipeline. However, challenges persist in its aesthetics division, where Juvederm sales fell 22.2% due to macroeconomic pressures and shifting consumer behavior. Despite these headwinds, the company’s strong R&D pipeline and absence of major patent expirations through the decade position it for sustained growth.

The strategy of buying the top 500 stocks by daily trading volume and holding them for one day from 2022 to now delivered moderate returns. The 1-day return was 0.98%, with a total return of 31.52% over 365 days. This indicates the strategy captured some short-term momentum but also reflected market volatility and potential timing risks.